BioTime is leading the regenerative revolution by developing and marketing a growing portfolio of advanced human stem cell-based products used by researchers working in universities, research institutions, bioscience and biopharmaceutical industries, as well as government laboratories worldwide. These products are developed internally or in conjunction with BioTime’s family of companies and are marketed through BioTime’s ESI BIO division (ESI BIO.com). Many of these products are provided at a research grade and a clinical grade, making it more efficient for researcher to transfer their research discoveries into clinical applications.
Current research products include:
- Human Embryonic Stem Cells (hESC) developed by BioTime’s Singapore-based subsidiary ES Cell International Pte Ltd. (“ESI”). ESI’s hESC are approved by the National Institutes of Health (“NIH”) and can be provided at a research grade or manufactured under current good manufacturing practices (‘cGMP).
- PureStem® human Embryonic Progenitors (hEP) that are unique progenitor cells derived from hESC and have a wide variety of advantages over pluripotent hESC as well as adult stem cells in scientific research and potential clinical applications.
- HyStem® hydrogel products, a family of unique biomaterials that can be used in the laboratory to mimic a living cell’s natural environment (called an extracellular matrix (ECM)). These materials have applications in cell culture, stem cell growth and tissue engineering. HyStem can be provided at a clinical grade, making them useful for regenerative medicine, cell based therapies, and as delivery vehicles for bioactive molecules.
- Cell culture reagents including culture media, small molecules, antibodies and kits for cell differentiation and reprogramming.
BioTime’s research products and technologies, including its hESC, its PureStem embryonic progenitor cells, its HyStem hydrogel products and its growing portfolio of stem cell culture reagents are protected by a strong portfolio of intellectual property developed internally, through its family of companies or licensed from other entities.